CRVS

Over the past six months, Corvus Pharmaceuticals' stock price has fluctuated significantly, with a 1-year change of +51.5% but a 1-month change of -27.7% as of October 2026. The company reported a Q1 2026 EPS of -$0.150 USD and a Q2 2026 net loss of $18.0 million with an EPS of -$0.19, missing estimates, which led to a slight share drop despite positive atopic dermatitis data. Positive soquelitinib data for atopic dermatitis showed durable benefit and no major safety concerns, leading to trial expansion into asthma and hidradenitis suppurativa, with a Phase 1b trial for hidradenitis suppurativa initiated in late September 2026. However, delays in clinical trial readouts, such as the Phase III PTCL interim futility analysis being pushed to Q1 2027, have caused investor concern. A public offering in January 2026 raised $189.4 million, bolstering the company's cash position to $215.2 million by Q2 2026, providing a cash runway into Q2 2028. Insider activity included a director buying 21,700 shares around June 2026, and analysts maintain a 'Strong Buy' or 'Moderate Buy' consensus rating with significant upside potential.